Setting

North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247646 | Pages: 91

North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach $569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region. Highlighted with 23 tables and 40 figures, this 91-page report “North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country. Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs Based on Influenza Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	5
1.1 Industry Definition and Research Scope	5
1.1.1 Industry Definition	5
1.1.2 Research Scope	6
1.2 Research Methodology	9
1.2.1 Overview of Market Research Methodology	9
1.2.2 Market Assumption	10
1.2.3 Secondary Data	10
1.2.4 Primary Data	10
1.2.5 Data Filtration and Model Design	12
1.2.6 Market Size/Share Estimation	13
1.2.7 Research Limitations	14
1.3 Executive Summary	15
2 Market Overview and Dynamics	17
2.1 Market Size and Forecast	17
2.1.1 Impact of COVID-19 on the Market	18
2.2 Major Growth Drivers	20
2.3 Market Restraints and Challenges	24
2.4 Emerging Opportunities and Market Trends	27
2.5 Porter’s Fiver Forces Analysis	31
3 Segmentation of North America Market by Product Type	35
3.1 Market Overview by Product Type	35
3.2 Oseltamivir Phosphate	37
3.3 Baloxavir Marboxil	38
3.4 Peramivir	39
3.5 Zanamivir	40
3.6 Other Drugs	41
4 Segmentation of North America Market by Influenza Type	42
4.1 Market Overview by Influenza Type	42
4.2 Influenza A	44
4.3 Influenza B	45
4.4 Influenza C	46
5 Segmentation of North America Market by Administration Route	47
5.1 Market Overview by Administration Route	47
5.2 Oral Administration	49
5.3 Other Administration Routes	50
6 Segmentation of North America Market by Distribution Channel	51
6.1 Market Overview by Distribution Channel	51
6.2 Retail Pharmacy	53
6.3 Hospital Pharmacy	54
6.4 Clinics	55
6.5 Online Stores	56
7 North America Market 2019-2030 by Country	57
7.1 Overview of North America Market	57
7.2 U.S.	60
7.3 Canada	64
7.4 Mexico	66
8 Competitive Landscape	68
8.1 Overview of Key Vendors	68
8.2 New Product Launch, Partnership, Investment, and M&A	71
8.3 Company Profiles	72
AstraZeneca Plc	72
BioCryst Pharmaceuticals Inc.	74
Biondvax	75
Daiichi Sankyo Company	76
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)	77
GlaxoSmithKline Plc	78
Mylan N.V	79
Natco Pharma Limited	80
Novartis AG	81
Sanofi	82
Seqirus	83
Teva Pharmaceutical Industries Limited	84
9 Investing in North America Market: Risk Assessment and Management	85
9.1 Risk Evaluation of North America Market	85
9.2 Critical Success Factors (CSFs)	88
Related Reports and Products	91
List Of Tables

Table 1.  Snapshot of North America Influenza Treatment Market, 2019-2030	16
Table 2.  Main Product Trends and Market Opportunities in North America Influenza Treatment Market	27
Table 3. North America Influenza Treatment Market by Product Type, 2019-2030, $ mn	35
Table 4. North America Influenza Treatment Market by Influenza Type, 2019-2030, $ mn	42
Table 5. North America Influenza Treatment Market by Administration Route, 2019-2030, $ mn	47
Table 6. North America Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	51
Table 7. North America Influenza Treatment Market by Country, 2019-2030, $ mn	58
Table 8. U.S. Influenza Treatment Market by Product Type, 2019-2030, $ mn	62
Table 9. U.S. Influenza Treatment Market by Administration Route, 2019-2030, $ mn	62
Table 10. U.S. Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	62
Table 11. Canada Influenza Treatment Market by Product Type, 2019-2030, $ mn	65
Table 12. Canada Influenza Treatment Market by Administration Route, 2019-2030, $ mn	65
Table 13. Canada Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	65
Table 14. Mexico Influenza Treatment Market by Product Type, 2019-2030, $ mn	67
Table 15. Mexico Influenza Treatment Market by Administration Route, 2019-2030, $ mn	67
Table 16. Mexico Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	67
Table 17. AstraZeneca Plc: Company Snapshot	72
Table 18. AstraZeneca Plc: Business Segmentation	72
Table 19. AstraZeneca Plc: Product Portfolio	73
Table 20. AstraZeneca Plc: Revenue, 2016-2018, $ mn	73
Table 21. AstraZeneca Plc: Recent Developments	73
Table 22.  Risk Evaluation for Investing in North America Market, 2019-2030	86
Table 23. Critical Success Factors and Key Takeaways	89
List Of Figures

Figure 1. Research Method Flow Chart	9
Figure 2. Breakdown of Primary Research	11
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	13
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	15
Figure 5. North America Influenza Treatment Market, 2019-2030, $ mn	17
Figure 6. Impact of COVID-19 on Business	18
Figure 7. Primary Drivers and Impact Factors of North America Influenza Treatment Market	20
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	23
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	23
Figure 10. Primary Restraints and Impact Factors of North America Influenza Treatment Market	24
Figure 11. Investment Opportunity Analysis	28
Figure 12. Porter’s Fiver Forces Analysis of North America Influenza Treatment Market	31
Figure 13. Breakdown of North America Influenza Treatment Market by Product Type, 2019-2030, % of Revenue	35
Figure 14. North America Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)	36
Figure 15. North America Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn	37
Figure 16. North America Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn	38
Figure 17. North America Influenza Treatment Market: Peramivir, 2019-2030, $ mn	39
Figure 18. North America Influenza Treatment Market: Zanamivir, 2019-2030, $ mn	40
Figure 19. North America Influenza Treatment Market: Other Drugs, 2019-2030, $ mn	41
Figure 20. Breakdown of North America Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue	42
Figure 21. North America Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)	43
Figure 22. North America Influenza Treatment Market: Influenza A, 2019-2030, $ mn	44
Figure 23. North America Influenza Treatment Market: Influenza B, 2019-2030, $ mn	45
Figure 24. North America Influenza Treatment Market: Influenza C, 2019-2030, $ mn	46
Figure 25. Breakdown of North America Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue	47
Figure 26. North America Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)	48
Figure 27. North America Influenza Treatment Market: Oral Administration, 2019-2030, $ mn	49
Figure 28. North America Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn	50
Figure 29. Breakdown of North America Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue	51
Figure 30. North America Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)	52
Figure 31. North America Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn	53
Figure 32. North America Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn	54
Figure 33. North America Influenza Treatment Market: Clinics, 2019-2030, $ mn	55
Figure 34. North America Influenza Treatment Market: Online Stores, 2019-2030, $ mn	56
Figure 35. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue	58
Figure 36. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	59
Figure 37. U.S. Influenza Treatment Market, 2019-2030, $ mn	61
Figure 38. Canada Influenza Treatment Market, 2019-2030, $ mn	64
Figure 39.  Influenza Treatment Market in Mexico, 2015-2030, $ mn	66
Figure 40. Growth Stage of North America Influenza Treatment Industry over the Forecast Period	68
Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca Plc	
BioCryst Pharmaceuticals Inc.	
Biondvax	
Daiichi Sankyo Company	
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)	
GlaxoSmithKline Plc	
Mylan N.V	
Natco Pharma Limited	
Novartis AG	
Sanofi	
Seqirus	
Teva Pharmaceutical Industries Limited